Complementary and antagonistic effects of combined glucagon‐like peptide‐2 and glucagon‐like peptide‐1 receptor agonist administration on parameters relevant to short bowel syndrome
- 26 November 2021
- journal article
- case report
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 46 (6) , 1361-1370
Abstract
Background: Short bowel syndrome (SBS) is characterized by malabsorption requiring parenteral nutrition. The intestinotrophic glucagon‐like peptide (GLP)‐2 receptor agonist, h[Gly2]GLP2, is used to treat patients with SBS. Evidence suggests that GLP‐1 receptor agonists such as exendin‐4 (Ex4) may be beneficial in SBS given their ability to increase intestinal growth and delay gastric emptying (GE).Methods: Intestinal growth, body weight (BW), food intake (FI), GE, gastrointestinal (GI) transit, intestinal permeability, and glucose tolerance were investigated in male and female C57/BL6 mice following vehicle, h[Gly2]GLP2, or Ex4 treatment, alone or in combination at “low,” “medium,” and “high” doses (0.1, 0.5, 1.0 and 0.01, 0.05, 0.1 μg/g, respectively).Results: Only the h[Gly2]GLP2 low/Ex4 high‐dose combination additively increased small intestinal (SI) weight compared with vehicle and both monoagonists (P < 0.01–0.001), via increased villus height (P < 0.01) and SI length (P < 0.05). This combination had no effects on BW; FI; and fat, liver, spleen, heart, and kidney weights but reduced GI transit (P < 0.001) versus low‐dose h[Gly2]GLP2 monotreatment and abrogated the inhibitory effects of high‐dose Ex4 on GE (P < 0.01) and of low‐dose h[Gly2]GLP2 on intestinal permeability (P < 0.05). Ex4‐induced improvements in glucose homeostasis were maintained upon combination with h[Gly2]GLP2 (P < 0.001).Conclusions: These findings suggest that combining specific doses of GLP‐2‐ and GLP‐1 receptor agonists additively improves SI growth and GI transit without detrimental effects on BW, FI, GE, and glucose homeostasis, and may be useful for the treatment of patients with SBS.Keywords
Funding Information
- Canadian Institutes of Health Research (PJT‐148523)
This publication has 49 references indexed in Scilit:
- Abdominal fat analyzed by DEXA scan reflects visceral body fat and improves the phenotype description and the assessment of metabolic risk in miceAmerican Journal of Physiology-Endocrinology and Metabolism, 2012
- Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weightDiabetes, Obesity and Metabolism, 2012
- Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndromeNeurogastroenterology & Motility, 2011
- Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndromeGut, 2011
- Agonist efficacy and receptor desensitization: from partial truths to a fuller pictureBritish Journal of Pharmacology, 2009
- Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeabilityGut, 2009
- Role of glial cell-line derived neurotropic factor family receptor α2 in the actions of the glucagon-like peptides on the murine intestineAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2007
- The Essential Role of Insulin-Like Growth Factor-1 in the Intestinal Tropic Effects of Glucagon-Like Peptide-2 in MiceGastroenterology, 2006
- Enteric Microbial Flora, Bacterial Overgrowth, and Short-Bowel SyndromeClinical Gastroenterology and Hepatology, 2006
- Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patientsGut, 2005